News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
743,171 Results
Type
Article (45709)
Company Profile (714)
Press Release (696735)
Multimedia
Podcasts (179)
Webinars (30)
Section
Business (211744)
Career Advice (2712)
Deals (37194)
Drug Delivery (157)
Drug Development (82712)
Employer Resources (179)
FDA (16692)
Job Trends (15898)
News (356768)
Policy (32730)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (2)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Genetown Elite (4)
2027 Genetown Standard (3)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
Academia (2201)
Academic (2)
Accelerated approval (49)
Adcomms (31)
Allergies (181)
Alliances (51994)
ALS (220)
Alzheimer's disease (1859)
Antibody-drug conjugate (ADC) (485)
Approvals (17034)
Artificial intelligence (735)
Autoimmune disease (311)
Automation (55)
Bankruptcy (385)
Best Places to Work (11770)
BIOSECURE Act (23)
Biosimilars (227)
Biotechnology (445)
Bladder cancer (185)
Brain cancer (74)
Breast cancer (756)
Cancer (5937)
Cardiovascular disease (505)
Career advice (2305)
Career pathing (48)
CAR-T (349)
CDC (48)
Celiac Disease (2)
Cell therapy (970)
Cervical cancer (48)
Clinical research (71719)
Collaboration (2208)
Company closure (8)
Compensation (1405)
Complete response letters (98)
COVID-19 (2750)
CRISPR (112)
C-suite (1185)
Cystic fibrosis (160)
Data (7926)
Decentralized trials (3)
Denatured (54)
Depression (176)
Dermatology (83)
Diabetes (606)
Diagnostics (7181)
Digital health (58)
Diversity (9)
Diversity, equity & inclusion (43)
Drug discovery (346)
Drug pricing (228)
Drug shortages (36)
Duchenne muscular dystrophy (295)
Earnings (93397)
Editorial (74)
Employer branding (24)
Employer resources (159)
Events (124722)
Executive appointments (1139)
FDA (20462)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1786)
Gene editing (253)
Generative AI (73)
Gene therapy (794)
GLP-1 (1213)
Government (4262)
Grass and pollen (8)
Guidances (407)
Healthcare (18572)
HIV (86)
Huntington's disease (60)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (101)
Immunology and inflammation (330)
Immuno-oncology (102)
Indications (190)
Infectious disease (3098)
Inflammatory bowel disease (233)
Inflation Reduction Act (15)
Influenza (139)
Intellectual property (296)
Interviews (526)
IPO (17479)
IRA (55)
Job creations (4491)
Job search strategy (1870)
JPM (68)
Kidney cancer (20)
Labor market (98)
Layoffs (663)
Leadership (46)
Legal (8235)
Liver cancer (101)
Longevity (32)
Lung cancer (776)
Lymphoma (427)
Machine learning (61)
Management (62)
Manufacturing (1107)
MASH (203)
Medical device (14594)
Medtech (14721)
Mergers & acquisitions (20963)
Metabolic disorders (1642)
mRNA (232)
Multiple sclerosis (189)
NASH (21)
Neurodegenerative disease (459)
Neuropsychiatric disorders (118)
Neuroscience (3448)
Neurotech (1)
NextGen: Class of 2026 (6780)
Non-profit (3816)
Now hiring (79)
Obesity (804)
Opinion (354)
Ovarian cancer (221)
Pain (264)
Pancreatic cancer (310)
Parkinson's disease (375)
Partnered (36)
Patents (613)
Patient recruitment (692)
Peanut (67)
People (62221)
Pharmaceutical (127)
Pharmacy benefit managers (33)
Phase 1 (22374)
Phase 2 (31686)
Phase 3 (23774)
Pipeline (8820)
Policy (339)
Postmarket research (2435)
Preclinical (9410)
Press Release (66)
Prostate cancer (307)
Psychedelics (63)
Radiopharmaceuticals (343)
Rare diseases (1156)
Real estate (6235)
Recruiting (77)
Regulatory (25735)
Reports (51)
Research institute (2125)
Resumes & cover letters (420)
Rett syndrome (39)
RNA editing (25)
RSV (91)
Schizophrenia (188)
Series A (314)
Series B (226)
Service/supplier (27)
Sickle cell disease (119)
Special edition (29)
Spinal muscular atrophy (171)
Sponsored (45)
Startups (4033)
State (2)
Stomach cancer (21)
Supply chain (133)
Tariffs (101)
The Weekly (122)
Vaccines (1153)
Venture capital (120)
Weight loss (555)
Women's health (123)
Worklife (24)
Date
Today (50)
Last 7 days (888)
Last 30 days (3613)
Last 365 days (31585)
2026 (12978)
2025 (31679)
2024 (36725)
2023 (41457)
2022 (52106)
2021 (56087)
2020 (54102)
2019 (46688)
2018 (35526)
2017 (34217)
2016 (33343)
2015 (38982)
2014 (32405)
2013 (27736)
2012 (29038)
2011 (29045)
2010 (27057)
Location
Africa (881)
Alabama (101)
Alaska (6)
Arizona (307)
Arkansas (14)
Asia (44650)
Australia (7401)
California (13608)
Canada (3802)
China (1425)
Colorado (582)
Connecticut (603)
Delaware (412)
Europe (99990)
Florida (1992)
Georgia (431)
Hawaii (4)
Idaho (63)
Illinois (1060)
India (98)
Indiana (632)
Iowa (25)
Japan (540)
Kansas (131)
Kentucky (52)
Louisiana (40)
Maine (84)
Maryland (1550)
Massachusetts (9910)
Michigan (399)
Minnesota (748)
Mississippi (7)
Missouri (152)
Montana (36)
Nebraska (27)
Nevada (145)
New Hampshire (88)
New Jersey (3614)
New Mexico (33)
New York (3522)
North Carolina (1816)
North Dakota (11)
Northern California (6788)
Ohio (406)
Oklahoma (26)
Oregon (51)
Pennsylvania (2693)
Puerto Rico (30)
Rhode Island (53)
South America (1260)
South Carolina (84)
South Dakota (1)
Southern California (5286)
Tennessee (205)
Texas (2142)
United States (48088)
Utah (391)
Vermont (1)
Virginia (344)
Washington D.C. (83)
Washington State (1115)
West Virginia (4)
Wisconsin (142)
Wyoming (2)
743,171 Results for "eli lilly and company".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.
April 1, 2026
·
3 min read
·
Heather McKenzie
Alzheimer’s disease
Biogen ready to catch Alzheimer’s patients transitioning off Lilly’s Kisunla
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer’s market as patients end their 18-month course of Lilly’s product.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company
April 15, 2026
·
2 min read
C-suite
Lilly, J&J CEOs top pharma’s highest paid list—again
Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by more than $4 million.
May 13, 2026
·
5 min read
·
Annalee Armstrong
Earnings
Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth
Eli Lilly’s $19.8 billion revenue for the first quarter could have been higher if not for declining prices for key medicines like Zepbound, Mounjaro and Taltz.
April 30, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
LifeMD® Now Offering Eli Lilly and Company’s Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
April 10, 2026
·
5 min read
diabetes
Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data demonstrating a clean safety profile and revealed plans to seek approval in the indication.
April 16, 2026
·
2 min read
·
Gabrielle Masson
Earnings
Lilly’s weight loss pill reaches brand new patients, even without full-court marketing press
Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for the weight loss pill.
April 30, 2026
·
3 min read
·
Annalee Armstrong
Manufacturing
Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site
Eli Lilly’s latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization.
May 8, 2026
·
1 min read
·
Gabrielle Masson
Obesity
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.
April 15, 2026
·
2 min read
·
Tristan Manalac
1 of 74,318
Next
